ViiV Healthcare Trial Met Primary Endpoint for HIV Shot
The phase 3b Crown trial demonstrated that injectable Cabenuva effectively suppresses HIV-1 in treatment-experienced patients.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you prefer long-acting injectable medications over daily oral treatments for managing chronic health conditions?
ViiV Healthcare has announced that its phase 3b Crown trial successfully reached its primary endpoint for the HIV treatment Cabenuva. The study evaluated direct initiation of the injectable regimen in 326 participants with detectable HIV-1 across eight countries.
Why it matters
The study addresses a clinical gap regarding the efficacy of Cabenuva in patients failing daily oral antiretroviral therapy. This result could shift standard-of-care protocols for patients struggling with adherence to traditional daily pill regimens.
The Crown trial demonstrated superior viral suppression rates for the cabotegravir and rilpivirine injection compared to daily oral therapy. Cabenuva is administered as an injection six times per year.
The players
ViiV Healthcare
A global specialist HIV company majority-owned by GSK with Pfizer and Shionogi as shareholders, focused on antiretroviral development.
GSK
A multinational pharmaceutical firm currently prioritizing its HIV portfolio, which accounted for a significant portion of its 2025 growth.
The details
Cabenuva utilizes a long-acting formulation of two antiretroviral drugs: cabotegravir, an integrase inhibitor that blocks viral DNA integration into host cells, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor that prevents viral replication. The study confirmed that patients with detectable viral loads could transition directly to this injectable regimen without developing resistance. Participants in the study population lacked prior resistance to these specific drug classes.
Timeline
2021: Cabenuva received initial regulatory approval.
2025: Cabenuva generated 1.4 billion pounds sterling in global sales.
October 6, 2026: ViiV announced the Crown trial met its primary endpoint.
The Tech Race
The Crown trial results follow the trajectory established by the Mocha study, which demonstrated high viral suppression rates in adolescent populations using Cabenuva. This finding strengthens ViiV's competitive position in the long-acting injectable market against traditional daily oral treatments.
Patients currently struggling with daily oral adherence may soon have a clinical path toward injectable treatment administered only six times annually. Availability and specific rollout timelines for this protocol remain subject to upcoming regulatory consultations.
The takeaway
This trial validates a shift toward bimonthly injectable therapy for those previously failing oral regimens. Stakeholders should watch for the detailed data presentation at upcoming medical meetings and subsequent regulatory filings.
Further reading
For more on the latest research in the field, visit Biotech.
Live Poll
Do you prefer long-acting injectable medications over daily oral treatments for managing chronic health conditions?
